02595.HK
GenFleet Therapeutics (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 25.90
+3.60%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenHKD 25.50
From 52W high−47.63%
Volume2.72M
Market capHKD 9.11B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
HKD 25.50
From 52W high
−47.63%
Volume
2.72M
Market cap
HKD 9.11B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
—
P/E (TTM)
—
RSI (14)
39.2
MomentumView details →
1D Return
+3.60%
YTD Return
+8.73%
Similar companies
Latest newsMore news →
GenFleet Therapeutics (02595) repurchased 80,000 of its own shares for HK$2.063 million at HK$25.32-26 per share on September 10, 2026.9d agoGenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has entered a Phase II study as first-line treatment for advanced non-small cell lung cancer with KRAS G12D mutation.25d agoGenFleet Therapeutics announced that its oral KRAS G12D inhibitor GFH375 has initiated a registrational Phase III clinical study for non-small cell lung cancer, with the first patient enrolled at Nanjing Drum Tower Hospital.41d ago